+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer

Plos One 5(5): E10471

Sperm protein (Sp17) is an attractive target for ovarian cancer (OC) vaccines because of its over-expression in primary as well as in metastatic lesions, at all stages of the disease. Our studies suggest that a Sp17-based vaccine can induce an enduring defense against OC development in C57BL/6 mice with ID8 cells, following prophylactic and therapeutic treatments. This is the first time that a mouse counterpart of a cancer testis antigen (Sp17) was shown to be expressed in an OC mouse model, and that vaccination against this antigen significantly controlled tumor growth. Our study shows that the CpG-adjuvated Sp17 vaccine overcomes the issue of immunologic tolerance, the major barrier to the development of effective immunotherapy for OC. Furthermore, this study provides a better understanding of OC biology by showing that Th-17 cells activation and contemporary immunosuppressive T-reg cells inhibition is required for vaccine efficacy. Taken together, these results indicate that prophylactic and therapeutic vaccinations can induce long-standing protection against OC and delay tumor growth, suggesting that this strategy may provide additional treatments of human OC and the prevention of disease onset in women with a family history of OC.

(PDF emailed within 0-6 h: $19.90)

Accession: 051926077

Download citation: RISBibTeXText

PMID: 20485677

DOI: 10.1371/journal.pone.0010471

Related references

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. Journal of Translational Medicine 11: 215, 2014

Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. Clinical Cancer Research 19(8): 2224-2231, 2013

Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clinical Cancer Research 13(5): 1421-1428, 2007

HPV-vaccination for the prevention of cervical cancer in Austria: a model based long-term prognosis of cancer epidemiology. Journal of Public Health 18(1): 3-13, 2010

Interactions between natural autoantibodies to tumor-associated human ovarian cancer antigen and murine ovarian cancer cells CaO-1. Bulletin of Experimental Biology and Medicine 127(2): 206-208, 1999

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Research 66(2): 1105-1113, 2006

Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors. Gynecologic Oncology 145(3): 413-419, 2017

Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer. Biomarkers in Cancer 7: 31-38, 2015

A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation. International Journal of Oncology 41(3): 1139-1147, 2013

BORIS, a novel cancer-testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Journal of Clinical Oncology 23(16_suppl): 9673-9673, 2016

Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays. European Journal of Gynaecological Oncology 36(3): 298-303, 2015

DNA vaccination against HuD antigen elicits antitumor activity in a small-cell lung cancer murine model. American Journal of Respiratory Cell and Molecular Biology 21(1): 37-43, 1999

Heat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer. American Journal of Cancer Research 7(6): 1252-1269, 2017

SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immunity 4: 10, 2004

DNA cancer vaccination strategies target SV40 large tumour antigen in a murine experimental metastasis model. Developments in Biologicals 104: 143-147, 2001